|
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). |
|
|
|
Honoraria - AstraZeneca; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche; Merck; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); OncoGenex (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Other Relationship - Roche |
|
|
Stock and Other Ownership Interests - AstraZeneca (I) |
|
Research Funding - AstraZeneca |
|
|
Honoraria - Merck; Novartis; Pfizer |
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Eisai; Pfizer; Roche |
Research Funding - AstraZeneca; Merck; Novartis; Pfizer |
Travel, Accommodations, Expenses - Merck; Novartis |
|
|
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Foundation Medicine; Kyowa Kirin; Lilly; Novartis; Pfizer; Roche; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
Stock and Other Ownership Interests - Mitox Therapeutics |
Honoraria - Eisai; Prosigna |
Consulting or Advisory Role - Shionogi |
Research Funding - Pathios Therapeutics |
Travel, Accommodations, Expenses - Roche |
|
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca |
|
|
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Eurofarma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche |
Research Funding - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche |
|
|
|
|
|
|
|
|
Employment - AstraZeneca; AstraZeneca/MedImmune; Pfizer |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Novartis; Roche; Takeda |